| Status | In progress |
| Decision | Selected |
| Process | TA |
| Referral date | 01 March 2015 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 3 November 2015 |
| 1st appraisal committee meeting: | 16 February 2016 |
Project Team
| Project lead | Liv Gualda |
Email enquiries
- If you have any queries please email TACommA@nice.org.uk
| External Assessment Group | Liverpool Reviews and Implementation Group (LRIG) |
Stakeholders
| Companies sponsors | Amgen |
| Others | Department of Health |
| NHS England | |
| Welsh Government | |
| Professional groups | Association of Cancer Physicians |
| British Association of Skin Cancer Specialist Nurses | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| UK Clinical Pharmacy Association | |
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Bristol-Myers Squibb Pharmaceutical (ipilimumab) |
| Roche Products (vemurafenib) | |
| Evidence review group | Liverpool Reviews and Implementation Group (LRIG) |
| General commentators | Department of Health, Social Services and Public Safety for Northern Ireland |
| Healthcare Improvement Scotland | |
| Relevant research groups | National Institute for Health Research Technology Assessment Programme (NETSCC)? |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 September 2016 | Expected publication |
| 09 August 2016 - 23 August 2016 | Final appraisal determination |
| 16 March 2016 - 13 April 2016 | Draft guidance: 508 |
For further information on our processes and methods, please see our CHTE processes and methods manual